Go Pro
→ WATCH THIS BEFORE SEPTEMBER 25TH!! (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evolus, Inc. stock logo
EOLS
Evolus
$8.06
+0.8%		$7.56
$3.86
▼
$9.31
$532.36M1.421.02 million shs31,011 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.06
+0.7%		$2.26
$1.10
▼
$2.68
$918.84M1.022.93 million shs206,668 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$3.67
-0.4%		$4.32
$2.04
▼
$12.46
$178.43M-0.08214,690 shs3,121 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evolus, Inc. stock logo
EOLS
Evolus
+1.65%+0.76%-4.77%+18.55%+27.03%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-0.49%+3.03%-11.30%-5.56%+71.43%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+0.55%-8.23%-23.97%-15.40%+81.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Evolus, Inc. stock logo
EOLS
Evolus
$8.06
+0.8%		$7.56
$3.86
▼
$9.31
$532.36M1.421.02 million shs31,011 shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.06
+0.7%		$2.26
$1.10
▼
$2.68
$918.84M1.022.93 million shs206,668 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$3.67
-0.4%		$4.32
$2.04
▼
$12.46
$178.43M-0.08214,690 shs3,121 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Evolus, Inc. stock logo
EOLS
Evolus
+1.65%+0.76%-4.77%+18.55%+27.03%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-0.49%+3.03%-11.30%-5.56%+71.43%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+0.55%-8.23%-23.97%-15.40%+81.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Evolus, Inc. stock logo
EOLS
Evolus
2.50
Moderate Buy$14.5080.30% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.25
Hold$4.55123.81% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.75
Reduce$10.33183.96% Upside

Current Analyst Ratings Breakdown

Latest LXRX, NERV, and EOLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2026
Evolus, Inc. stock logo
EOLS
Evolus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/25/2026
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$13.00
8/14/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Mixed$7.50 ➝ $10.00
8/12/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
8/3/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/23/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/8/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/3/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/24/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Evolus, Inc. stock logo
EOLS
Evolus
$297.18M1.79N/AN/A($0.36) per share-22.34
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$49.80M18.16N/AN/A$0.30 per share6.78
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/A($3.25) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Evolus, Inc. stock logo
EOLS
Evolus
-$51.64M-$0.52N/A100.53N/A-10.85%N/A-13.00%11/4/2026 (Estimated)
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$50.34M-$0.15N/AN/AN/A-147.38%-37.53%-24.96%11/5/2026 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$293.42M-$28.87N/AN/AN/AN/AN/A-31.72%11/4/2026 (Estimated)

Latest LXRX, NERV, and EOLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.1933-$0.14+$0.0533-$0.14N/AN/A
8/6/2026Q2 2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.0502-$0.06-$0.0098-$0.07$3.99 million$0.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Evolus, Inc. stock logo
EOLS
Evolus
N/A
1.70
1.28
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.29
13.37
13.29
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
20.15
20.14

Institutional Ownership

CompanyInstitutional Ownership
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%

Insider Ownership

CompanyInsider Ownership
Evolus, Inc. stock logo
EOLS
Evolus
5.00%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
14.00%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Evolus, Inc. stock logo
EOLS
Evolus
35366.05 million62.75 millionOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
81444.96 million382.66 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
747.75 million46.94 millionNot Optionable

Recent News About These Companies

Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200-Day Moving Average - Here's Why
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-minerva-neurosciences-nasdaq-nerv-share-price-crosses-below-200-day-moving-average-heres-why-2026-09-16/
Brokerages Set Minerva Neurosciences, Inc (NASDAQ:NERV) Target Price at $10.33
September 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31020116
Minerva Neurosciences, Inc (NASDAQ:NERV) Receives Consensus Recommendation of "Reduce" from Brokerages
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-minerva-neurosciences-inc-nasdaq-nerv-receives-consensus-recommendation-of-reduce-from-brokerages-2026-09-08/
Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200-Day Moving Average - Here's What Happened
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-minerva-neurosciences-nasdaq-nerv-shares-cross-below-200-day-moving-average-heres-what-happened-2026-09-04/
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352656/32445/en/minerva-neurosciences-to-participate-in-two-upcoming-investor-conferences.html
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
August 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/07/3341026/32445/en/minerva-neurosciences-provides-second-quarter-2026-financial-results-and-business-updates.html
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304700/32445/en/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs.html
Minerva Neurosciences Launches ATM Offering to Fund Trial
May 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/minerva-neurosciences-launches-atm-offering-to-fund-trial?utm_source=marketbeat.com&utm_medium=referral
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2924280/all-you-need-to-know-about-minerva-neurosciences-nerv-rating-upgrade-to-buy?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2924280
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2923961/minerva-neurosciences-nerv-loses-37-5-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=cs-stocknewsapi-ft-tale_of_the_tape|rsi-2923961
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3297009/32445/en/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference.html
Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
May 5, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68397606-minerva-neurosciences-inc-minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates-399.htm
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287601/32445/en/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates.html
Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/minerva-neurosciences-nerv-price-target-increased-by-31-03-to-9-69/ar-AA21TjoN
Citizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform Recommendation
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/citizens-initiates-coverage-of-minerva-neurosciences-nerv-with-market-outperform-recommendation/ar-AA210hf9
Minerva launched with New Outperform at Citizens on schizophrenia candidate
April 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4575323-minerva-stock-wins-new-outperform-citizens
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline
April 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/minerva-neurosciences-sets-2026-annual-shareholder-meeting-timeline?utm_source=marketbeat.com&utm_medium=referral
Minerva Announces Leadership Transition
April 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/02/3267830/32445/en/minerva-announces-leadership-transition.html
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3266016/32445/en/minerva-neurosciences-announces-first-patient-screened-in-global-phase-3-confirmatory-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia.html
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia
March 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4887464-minerva-neurosciences-plodding-ahead-after-another-roluperidone-delay
Minerva Neurosciences (NERV) price target increased by 61.11% to 7.40
March 27, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/minerva-neurosciences-nerv-price-target-increased-by-6111-to-740/ar-AA1Zw7Wt

New MarketBeat Followers Over Time

Media Sentiment Over Time

Evolus stock logo

Evolus NASDAQ:EOLS

$8.06 +0.07 (+0.81%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.06 +0.02 (+0.74%)
As of 10:26 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$3.67 -0.01 (-0.35%)
As of 10:27 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas